BIOMAT Database Logo BIOMAT Database Logo

[Prazosin in the treatment of hypertension: effect on lipid metabolism]. 1987

G Hitzenberger, and K Neumann, and S Dietz, and H Egger, and K Hariri, and E Kittler, and W Niedrist, and R Nitsch-Fritz, and O Ravanelli, and H Sapinsky
Abteilung für Klinische Pharmakologie, I. Medizinischen Universitätsklinik Wien.

In an open, non-comparative study, the effect of Prazosin, a selective and competitive inhibitor of alpha-adrenergic receptors, on blood pressure and lipid metabolism was studied in out-patients with hypertension. The pronounced antihypertensive effect of this vasodilator was confirmed. In almost all patients, i.e. in 144 of 171 patients with monotherapy, Prazosin caused a significant decrease of diastolic blood pressure within 3 to 6 weeks (in sitting position reduction to values below 90 mm Hg). This confirms the established antihypertensive effect due to vasodilation. In addition, Prazosin therapy is associated with a significant reduction in total cholesterol (p less than 0.001), a significant increase of HDL-cholesterol (p less than 0.001), a significant reduction of triglycerides (p less than 0.01) during the study period of 26 weeks. Prazosin monotherapy had a more pronounced influence on serum lipids than the combination of Prazosin with a diuretic. Prazosin was tolerated well; only during the first treatment weeks, a higher frequency of side effects due to abrupt reduction of blood pressure was observed, closely correlating with a too rapid increase of daily dose. Due to its proven antihypertensive effect and its favorous influence on lipid metabolism, Prazosin is suited for long-term treatment of hypertension, thus reducing two major risk factors, associated with coronary heart disease.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008055 Lipids A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed) Lipid
D008076 Cholesterol, HDL Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol. High Density Lipoprotein Cholesterol,Cholesterol, HDL2,Cholesterol, HDL3,HDL Cholesterol,HDL(2) Cholesterol,HDL(3) Cholesterol,HDL2 Cholesterol,HDL3 Cholesterol,alpha-Lipoprotein Cholesterol,Cholesterol, alpha-Lipoprotein,alpha Lipoprotein Cholesterol
D011224 Prazosin A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION. Furazosin,Minipress,Pratsiol,Prazosin HCL,Prazosin Hydrochloride,HCL, Prazosin,Hydrochloride, Prazosin
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014280 Triglycerides An ester formed from GLYCEROL and three fatty acid groups. Triacylglycerol,Triacylglycerols,Triglyceride

Related Publications

G Hitzenberger, and K Neumann, and S Dietz, and H Egger, and K Hariri, and E Kittler, and W Niedrist, and R Nitsch-Fritz, and O Ravanelli, and H Sapinsky
Effect of prazosin treatment on carbohydrate and lipoprotein metabolism in patients with hypertension.
January 1989, The American journal of medicine,
G Hitzenberger, and K Neumann, and S Dietz, and H Egger, and K Hariri, and E Kittler, and W Niedrist, and R Nitsch-Fritz, and O Ravanelli, and H Sapinsky
Prazosin versus captopril as initial therapy. Effect on hypertension and lipid levels.
January 1987, The American journal of medicine,
G Hitzenberger, and K Neumann, and S Dietz, and H Egger, and K Hariri, and E Kittler, and W Niedrist, and R Nitsch-Fritz, and O Ravanelli, and H Sapinsky
Effect of prazosin treatment on HDL kinetics in patients with hypertension.
October 1990, American journal of hypertension,
G Hitzenberger, and K Neumann, and S Dietz, and H Egger, and K Hariri, and E Kittler, and W Niedrist, and R Nitsch-Fritz, and O Ravanelli, and H Sapinsky
[The effect of prazosin on blood pressure and lipid status in patients with arterial hypertension].
January 1985, Vojnosanitetski pregled,
G Hitzenberger, and K Neumann, and S Dietz, and H Egger, and K Hariri, and E Kittler, and W Niedrist, and R Nitsch-Fritz, and O Ravanelli, and H Sapinsky
Prazosin in the treatment of hypertension.
August 1977, The Medical journal of Australia,
G Hitzenberger, and K Neumann, and S Dietz, and H Egger, and K Hariri, and E Kittler, and W Niedrist, and R Nitsch-Fritz, and O Ravanelli, and H Sapinsky
Prazosin in the treatment of hypertension.
February 1975, The Practitioner,
G Hitzenberger, and K Neumann, and S Dietz, and H Egger, and K Hariri, and E Kittler, and W Niedrist, and R Nitsch-Fritz, and O Ravanelli, and H Sapinsky
[Prazosin in the treatment of hypertension].
February 1977, Polski tygodnik lekarski (Warsaw, Poland : 1960),
G Hitzenberger, and K Neumann, and S Dietz, and H Egger, and K Hariri, and E Kittler, and W Niedrist, and R Nitsch-Fritz, and O Ravanelli, and H Sapinsky
Prazosin in the treatment of hypertension.
January 1977, Indian heart journal,
G Hitzenberger, and K Neumann, and S Dietz, and H Egger, and K Hariri, and E Kittler, and W Niedrist, and R Nitsch-Fritz, and O Ravanelli, and H Sapinsky
Prazosin in the treatment of hypertension.
June 1975, Clinical science and molecular medicine. Supplement,
G Hitzenberger, and K Neumann, and S Dietz, and H Egger, and K Hariri, and E Kittler, and W Niedrist, and R Nitsch-Fritz, and O Ravanelli, and H Sapinsky
Comparison of the effect of indoramin and prazosin on blood pressure and lipid profiles in essential hypertension.
January 1986, Journal of cardiovascular pharmacology,
Copied contents to your clipboard!